Question 1

What is Insulin degludec?

Accepted Answer

Insulin degludec is a Other.

Question 2

How often does Insulin degludec appear in global news?

Accepted Answer

Tracked across 1 news events drawn from 8 articles.

Question 3

When was Insulin degludec first tracked by Ergen?

Accepted Answer

First tracked on Jun 12, 2026.

Question 4

When was Insulin degludec last mentioned in news?

Accepted Answer

Last active on Jun 12, 2026.

Question 5

What is Insulin degludec's current news sentiment?

Accepted Answer

Aggregate sentiment score: -10 on a -100 to +100 scale (negative = critical coverage, positive = favorable coverage).

Question 6

How prominent is Insulin degludec in global news coverage?

Accepted Answer

Attention score of 7, derived from article volume and coverage intensity across 1 events.

Question 7

What is the most recent event involving Insulin degludec?

Accepted Answer

Gan & Lee's Insulin, Bofanglutide Success (Jun 12, 2026, 8 articles).

Question 8

How did the "Gan & Lee's Insulin, Bofanglutide Success" event impact Insulin degludec?

Accepted Answer

Insulin degludec (Tresiba) was used as a comparator in the SUPER-2 clinical trial for Insulin ludefen, which demonstrated superiority over it in reducing HbA1c levels.

Question 9

How is this data collected?

Accepted Answer

Ergen aggregates thousands of global news sources and extracts structured events, entities, and relationships with sentiment and attention metrics. Pages are daily static snapshots from the platform's live database.